Nucleix

About

Headcount over time

Offices

Q&A

What is Nucleix's primary focus?

Nucleix is a liquid biopsy company dedicated to revolutionizing cancer treatment through earlier disease detection, utilizing PCR-based epigenetics and methylation-based identification.

What is the total amount of funding Nucleix has raised to date?

Nucleix has raised a total of $143 million in funding.

Which product of Nucleix received FDA 510(k) Clearance recently?

In May 2023, Nucleix's Bladder EpiCheck® received FDA 510(k) Clearance for monitoring non-muscle invasive bladder cancer (NMIBC) recurrence.

What is the current employee count for Nucleix?

Nucleix has 72 employees, falling within the 51-200 employee bucket.

What is the status of Nucleix's Lung EpiCheck® test?

Nucleix is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, and data on its EpiCheck® Lung Cancer Atlas was premiered in April 2023 at the American Association for Cancer Research Annual Meeting.

What accreditations and certifications did Nucleix receive for its San Diego laboratory?

In October 2022, Nucleix received CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory.

Which clinical guidelines include Nucleix's Bladder EpiCheck®?

In March 2022, Bladder EpiCheck® was included in the 2022.

Team · 10

Danny Frumkin

Founder · Co-founder, VP Research

Adam Wasserstrom

Founder · Co-founder, VP Software & Analytics

Chris Hibberd

Executive Chairman & CEO

Todd Myers

CFO

Eli Frydman

President - EMEA

Catherine Schnabel

Chief Scientific Officer

Radha Duttagupta

VP Clinical Affairs

Aharona Shuali

VP, Medical

Eran Bram

VP, Product Development

Ricardo A.J. Ten Velden

VP, Sales & Marketing

Sectors & technology

Highlights

Tags